Amy Schmetzer
Critical Care Medicine · Pittsburgh, PANPI 1083178826
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (57.3%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 15 manufacturers reported payments, led by Regeneron Healthcare Solutions, Inc. at 30.1% of the total. Reporting peaked in 2023 at $4,592 and has fallen 81.5% since, to $849 in 2025. Among critical care medicine clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 171 payments — averaging $75.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$4K
- AstraZeneca$4K
- Sanofi$2K
- GSK$1K
- Boehringer Ingelheim$582
- Electromed, Inc.$299
- plus $647 from 9 others
What the payments were for
- Consulting fees$4,20833%
- Travel & lodging$1,28310%
- Food & beverage$7,39457%
- Education$110%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 21 | $3,876 |
| AstraZeneca | 63 | $3,828 |
| Sanofi | 14 | $2,275 |
| GSK | 30 | $1,390 |
| Boehringer Ingelheim | 13 | $582 |
| Electromed, Inc. | 12 | $299 |
| Amgen | 4 | $230 |
| Pulmonx Corporation | 2 | $109 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $102 |
| Mylan Specialty L.p. | 4 | $74 |
| Teva Pharmaceuticals USA, Inc. | 3 | $62 |
| Grifols USA, LLC | 1 | $22 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $17 |
| Verona Pharma, Inc. | 1 | $16 |
| Genentech USA, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,896 in reported general payments places this provider in the 90th percentile of 354 critical care medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 11 | $150,309 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 135 | $115,252 |
| Breo ElliptaFluticasone/Vilanterol | 60 | $26,394 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 29 | $20,946 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 34 | $17,564 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 55 | $9,462 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 13 | $6,121 |
| SymbicortBudesonide/Formoterol Fumarate | 21 | $5,491 |
| Incruse ElliptaUmeclidinium Bromide | 15 | $5,379 |
| Azelastine Hcl | 156 | $3,305 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 117 | $3,113 |
| Ventolin HfaAlbuterol Sulfate | 31 | $1,649 |
| Levalbuterol Tartrate HfaLevalbuterol Tartrate | 15 | $1,188 |
| Fluticasone Propionate | 77 | $482 |
| Montelukast Sodium | 80 | $427 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $1,390 | $164,590244 claims |
| Boehringer IngelheimOfev, Stiolto Respimat | $582 | $156,43024 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $3,828 | $26,43750 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 354 critical care medicine providers in Pennsylvania.
Other critical care medicine in Pittsburgh
- Briana DisilvioPittsburgh$204K
- Meilin YoungPittsburgh$182K
- Kees PoldermanPittsburgh$85K
- Michael RisbanoPittsburgh$34K
- Raghavan MuruganPittsburgh$33K
- Eric BihlerPittsburgh$22K
- Tiffany DumontPittsburgh$21K
- Stephanie BaltajiPittsburgh$10K
- Billie BarkerPittsburgh$10K
- Douglas WhitePittsburgh$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.